Eli Lilly & Co. (LLY) Announces Ixekizumab Phase 3 Met Primary, Secondary Endpoints in Psoriasis
Tweet Send to a Friend
Eli Lilly & Co. (NYSE: LLY) announced that detailed results of two pivotal Phase III studies for ixekizumab were published ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE